BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Stem Cells » MSCs » Page 54

Mesenchymal Stem Cells (MSCs)

Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).

Mesenchymal Stem Cell Industry News Round Up | October 2015

October 14, 2015 By Cade Hildreth (CEO) Leave a Comment

MESENCHYMAL STEM CELL INDUSTRY NEWS ROUND UP | OCTOBER 2015

The mesenchymal stem cell (MSC) industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.

Therefore, we are excited to share with you the following summary of major mesenchymal stem cell (MSC) industry events for  October 2015.

[Read more…]

Filed Under: MSCs Tagged With: current events, industry news, market research, mesenchymal stem cells, MSC, news round up, stem cell research

Top 10 Most Shared Stem Cell Articles of the Past 12 Months

September 30, 2015 By Cade Hildreth (CEO) Leave a Comment

Top 10 Most Shared Stem Cell Articles of Past 12 Months

Social Analytics Reveal Key Findings about Stem Cell Article Popularity

The field of stem cell research has boomed over the past twelve months, bringing to light new ideas for treatments and applications. Here at BioInformant, we strive to do our best to provide you with the most up to date information related to the industry. As a supplement to our monthly round-ups, we thought it would be important to share the top ten most shared stem cell articles from the past year.
[Read more…]

Filed Under: HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells Tagged With: market research, metrics, social analytics, stem cell news, stem cells, top shared stem cell articles

Market Penetration for Cord Tissue Storage in the U.S.

September 16, 2015 By Cade Hildreth (CEO) Leave a Comment

While the cord blood banking industry emerged in the late 1980’s and early 1990’s, the cord tissue storage industry didn’t emerge until much later when a Taiwanese company launched the service in 2008 (Healthbank Biotech). By 2009, two companies in Hong Kong were offering the service of cord tissue storage. It took until 2010 for the first U.S. cord blood bank, Cord Blood Registry (CBR) to offer the service, which it started in July 2010.

Today, the majority of private U.S. cord blood banks offer the service. A more in-depth analysis of the rate of market penetration within the U.S. is provided below.

History of Cord Tissue Storage

When an analysis of cord tissue storage was first completed by BioInformant in 2013, only nine companies where offering the service in the United States. These companies are shown in the table below. [Read more…]

Filed Under: Cord Blood, HSCs, MSCs Tagged With: cord blood, cord tissue, market trends

Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)

September 14, 2015 By Cade Hildreth (CEO) Leave a Comment

Currently, there are a number of clinical trials that are investigating the therapeutic potential of mesenchymal stem cells derived from umbilical cord tissue, often called Wharton’s Jelly.

Specific conditions that have been or are now being researched for their potential to be treated with stem cells derived from cord tissue include:

  • Cartilage repair
  • Diabetes
  • Heart disease
  • Human Immunodeficiency Virus (HIV)
  • Liver disease
  • Stroke
  • Serious wounds
  • Spinal Cord Injury

Clinical trials currently listed as involving the use of cord-tissue derived mesenchymal stem cells include:

  1. “Intracoronary or Intravenous Infusion Human Wharton’ Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy”
  2. “Intracoronary Human Wharton’s Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI)”

To search for more clinical trials using CT-MSCs, head to ClinicalTrials.gov and search for the following terms: 

  • “Wharton’s Jelly” AND “Mesenchymal Stem Cell”
  • “Wharton’s Jelly” AND “Mesenchymal Stem Cells”
  • “Umbilical Cord Tissue” AND “Mesenchymal Stem Cell”
  • “Umbilical Cord Tissue” AND “Mesenchymal Stem Cells”

ClinicalTrials.gov is website maintained by the U.S. National Institutes of Health (NIH) that is a “registry and results database of publicly and privately supported clinical studies of human participants from around the world.” While an excellent resource, it does not include all clinical trials worldwide, including some which may be listed on international registries.  

These searches will capture clinical trials that use varied vocabulary, as well as both singular and plural descriptions of the cell type. Other searches may be effective as well.

Neonatal Sources of Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) can also be derived from other tissue sources besides the newborn umbilical cord.

Specifically, MSCs can be derived from adult sources that include adipose tissue, peripheral blood, and bone marrow, as well as from neonatal tissues that include parts of the placenta and umbilical cord, as explored in the image below. This is significant because pre-clinical and clinical advances with the use of MSCs derived from other sources than cord tissue will create a greater willingness to explore medical applications for cord tissue-derived MSCs.

IMAGE.  SOURCES OF MESENCHYMAL STEM CELLS

SOURCES OF MESENCHYMAL STEM CELLS

About Us

BioInformant is the first and only market research firm to specialize in the stem cell industry. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been featured on news outlets including the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. 

Filed Under: Cord Blood, MSCs, Stem Cells Tagged With: clinical trials, cord tissue, cord tissue derived mesenchymal stem cell, CT-MSCs, mesenchymal stem cells, Wharton's Jelly

Market Forces Affecting the Cord Blood and Cord Tissue Industry

September 9, 2015 By Cade Hildreth (CEO) Leave a Comment

Market Forces Affecting the Cord Blood and Cord Tissue Industry

Recently released, the “Complete 2015-16 Global Cord Blood Banking Industry Report” explores new clinical trial market data supporting applications for hematopoietic stem cells (HSCs) from cord blood and mesenchymal stem cells (MSCs) from cord tissue. Within this rapidly evolving marketplace, those who choose to commit to understanding current opportunities and threats will be positioned for a substantial strategic advantage.

Because the global cord blood banking industry has matured substantially over the past few years, new market forces have created both serious threats and novel opportunities.   [Read more…]

Filed Under: Cord Blood, HSCs, MSCs Tagged With: cord blood banking, market intelligence, market news, metrics, trends

  • « Previous Page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • …
  • 58
  • Next Page »

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97

Featured Posts

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

iPSC derived cell therapeutics

The Pipeline for iPSC-Derived Cell Therapeutics in 2022

Stem cell companies

List of Stem Cell Companies Worldwide (2022)

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.